PDGFB and dermatofibrosarcoma protuberans: The PDGF receptor inhibitor imatinib showed efficacy in COL1A1‐PDGFB‐positive dermatofibrosarcoma protuberans as adjuvant therapy, confirming the importance of the PDGF‐BB autocrine loop in tumour growth.33